Correction to “Drug Reactions a Risk with NOAC Treatment for Afib”

In the April 22, 2025, I.M. Matters Weekly from ACP, the introduction to the research summary on drug reactions with non-vitamin K oral anticoagulants (NOACs) in nonvalvular afib listed atorvastatin as a medication associated with adverse events and death. However, while the study in question found that atorvastatin was one of the most commonly prescribed concomitant drugs that could potentially interact with a NOAC, it was not associated with adverse outcomes and in fact was associated with a significant reduction in all-cause mortality. The introduction to the summary has been updated in last week's issue.